Search
Jingxin Pharmaceutical has entered into a patent license agreement with Gedeon Richter, securing an exclusive right to develop, manufacture, and market formulations and active pharmaceutical ingredients (APIs) of cariprazine hydrochloride in mainland China. Cariprazine hydrochloride, an atypical antipsychotic medication, is primarily prescribed for the treatment of adult schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, bipolar depression, and as an adjunct therapy for major depressive disorder. Under the terms of the agreement, Jingxin Pharmaceutical will make milestone payments amounting to a maximum of €530,000 and will subsequently pay royalties based on the net sales of the product within the licensed territory post-market launch.
-
C114 Communication Network -
Communication Home
